What is BPC-157?
BPC-157 is a synthetic peptide based on a sequence found in a protein in human gastric juice. In wellness and athletic communities it is promoted for repairing tendons, ligaments, muscle and gut tissue, and it features in popular peptide “stacks.” It has never been approved as a medicine in the United States.
What the evidence shows
Human evidence is minimal. A 2025 systematic review of orthopedic and sports-medicine use (Vasireddi et al., PMID 40756949) identified 36 studies — 35 preclinical and only one clinical. The main human dataset is a small, uncontrolled retrospective review of about 16 knee-pain patients. A Phase II placebo-controlled hamstring-strain trial (NCT07437547) is recruiting in 2026 with no results yet; an earlier oral Phase I (NCT02637284) studied healthy volunteers. The FDA placed BPC-157 in Category 2 in 2023, citing concerns including immunogenicity, peptide-related impurities, and insufficient human data.
Is it legal?
BPC-157 is not FDA-approved. In April 2026 it was removed from FDA Category 2 but not moved to the approved Category 1 list, so legal compounding is not authorized; the PCAC reviews it on July 23, 2026.
Will BPC-157 become legal in 2026?+
Is “research-grade” BPC-157 the same as a medicine?+
Primary sources: 2025 review: PMID 40756949 · trials: ClinicalTrials.gov NCT07437547, NCT02637284 · FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. BPC-157 is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.